Figure 6.

Effect of rTSA-1 formulation on therapeutic vaccine control of parasitemia.

rTSA-1 antigen was formulated with MPLA at different doses (A), or with E6020 (B) or GLA-SE (C) as adjuvants, and infected mice were treated with two doses of vaccine at days 7 and 14 post-infection (N = 4 to 7 mice per group). Parasitemia was measured to assess vaccine efficacy in controlling infection. (A) Formulation with MPLA at 10 µg/dose was the best formulation compared to MPLA at 5 µg and 15 µg (ANOVA, F = 2.67, P = 0.04). (B) Formulation of rTSA-1 with E6020 and E6020 alone also allowed to control parasitemia (ANOVA, F = 10.26, P < 0.001). (C) Similarly, formulation of rTSA1 with GLA-SE and GLA-SE alone significantly reduced parasitemia (ANOVA, F = 4.89, P = 0.009). * indicates a significant differences with the saline group as determined by post-hoc Dunn’s test (P < 0.05).